Christopher Sweeney highlights the key questions arising from the primary endpoint analysis of the IPATential150 study of ipatasertib plus abiraterone in metastatic castration-resistant prostate cancer (3:54).
20-09-2020 | ESMO 2020 | Conference coverage | Video